Skip to main content
  1. Right Decisions
  2. Maternity & Gynaecology Guidelines
  3. Gynaecology
  4. Gynaecology guidelines
  5. Back
  6. Guidelines A-Z (all Gynaecology guidelines)
  7. Management of Bartholin’s cyst and abscess, Gynaecology (066)
Important: please update your RDS app to version 4.7.3

Welcome to the March 2025 update from the RDS team

1.     RDS issues - resolutions

1.1 Stability issues - Tactuum implemented a fix on 24th March which we believe has finally addressed the stability issues experienced over recent weeks.  The issue seems to have been related to the new “Tool export” function making repeated calls for content when new toolkit nodes were opened in Umbraco. No outages have been reported since then, and no performance issues in the logs, so fingers crossed this is now resolved.

1.2 Toolkit URL redirects failing– these were restored manually for the antimicrobial calculators on the 13th March when the issue occurred, and by 15th March for the remainder. The root cause was traced to adding a new hostname for an app migrated from another health board and made live that day. This led to the content management system automatically creating internal duplicate redirects, reaching the maximum number of permitted redirects and most redirects therefore ceasing to function.

This issue should not happen again because:

  • All old apps are now fully migrated to RDS. The large number of migrations has contributed to the high number of automated redirects.
  • If there is any need to change hostnames in future, Tactuum will immediately check for duplicates.

1.3 Gentamicin calculators – Incidents have been reported incidents of people accessing the wrong gentamicin calculator for their health board.  This occurs when clinicians are searching for the gentamicin calculator via an online search engine - e.g. Google - rather than via the health board directed policy route. When accessed via an external search engine, the calculator results are not listed by health board, and the start page for the calculator does not make it clearly visible which health board calculator has been selected.

The Scottish Antimicrobial Prescribing Group has asked health boards to provide targeted communication and education to ensure that clinicians know how to access their health board antimicrobial calculators via the RDS, local Intranet or other local policy route. In terms of RDS amendments, it is not currently possible to change the internet search output, so the following changes are now in progress:

  • The health board name will now be displayed within the calculator and it will be made clear which boards are using the ‘Hartford’ (7mg/kg) higher dose calculator
  • Warning text will be added to the calculator to advise that more than one calculator is in use in NHS Scotland and that clinicians should ensure they access the correct one for their health board. A link to the Right Decision Service list of health board antimicrobial prescribing toolkits will be included with the warning text. Users can then access the correct calculator for their Board via the appropriate toolkit.

We would encourage all editors and users to use the Help and Support standard operating procedure and the Editors’ Teams channel to highlight issues, even if you think they may be temporary or already noted. This helps the RDS team to get a full picture of concerns and issues across the service.

 

2.     New RDS presentation – RDS supporting the patient journey

A new presentation illustrating how RDS supports all partners in the patient journey – multiple disciplines across secondary, primary, community and social care settings – as well as patients and carers through self-management and shared decision-making tools – is now available. You will find it in the Promotion and presentation resources for editors section of the Learning and support toolkit.

3.     User guides

A new user guide is now available in the Guidance and tips section of Resources for providers within the Learning and Support area, explaining how to embed content from Google Calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream and Jotforms into RDS pages. A webinar for editors on using this new functionality is scheduled for 1 May 3-4 pm (booking information below.)

A new checklist to support editors in making all the checks required before making a new toolkit live is now available at the foot of the “Request a new toolkit” standard operating procedure. Completing this checklist is not a mandatory part of the governance process, but we would encourage you to use it to make sure all the critical issues are covered at point of launch – including organisational tags, use of Alias URLs and editorial information.

4.Training sessions for RDS editors

Introductory webinars for RDS editors will take place on:

  • Tuesday 29th April 4-5 pm
  • Thursday 1st May 4-5 pm

Special webinar for RDS editors – 1 May 3-4 pm

This webinar will cover:

  1. a) Use of the new left hand navigation option for RDS toolkits.
  2. b) Integration into RDS pages of content from external sources, including Google Calendar, Google Maps and simple Jotforms calculators.

Running usage statistics reports using Google analytics

  • Wednesday 23rd April 2pm-3pm
  • Thursday 22nd May 2pm-3pm

To book a place on any of these webinars, please contact Olivia.graham@nhs.scot providing your name, role, organisation, title and date of the webinar you wish to attend.

5.New RDS toolkits

The following toolkits were launched during March 2025:

SIGN guideline - Prevention and remission of type 2 diabetes

Valproate – easy read version for people with learning disabilities (Scottish Government Medicines Division)

Obstetrics and gynaecology induction toolkit (NHS Lothian) – password-protected, in pilot stage.

Oral care for care home and care at home services (Public Health Scotland)

Postural care in care homes (NHS Lothian)

Quit Your Way Pregnancy Service (NHS GGC)

 

6.New RDS developments

Release of the redesign of RDS search and browse, archiving and version control functionality, and editing capability for shared content, is now provisionally scheduled for early June.

The Scottish Government Realistic Medicine Policy team is leading development of a national approach to implementation of Patient-Reported Outcome Measures (PROMs) as a key objective within the Value Based Health and Care Action Plan. The Right Decision Service has been commissioned to deliver an initial version of a platform for issuing PROMs questionnaires to patients, making the PROMs reports available from patient record systems, and providing an analytics dashboard to compare outcomes across services.  This work is now underway and we will keep you updated on progress.

The RDS team has supported Scottish Government Effective Prescribing and Therapeutics Division, in partnership with Northern Ireland and Republic of Ireland, in a successful bid for EU funding to test develop, implement and assess new integrated care pathways for polypharmacy, including pharmacogenomics. As part of this project, the RDS will be working with NHS Tayside to test extending the current polypharmacy RDS decision support in the Vision primary care electronic health record system to include pharmacogenomics decision support.

7. Implementation projects

We have just completed a series of three workshops consulting on proposed improvements to the Being a partner in my care: Realistic Medicine together app, following piloting on 10 sites in late 2024. This app has been commissioned by Scottish Government Realistic Medicine to support patients and citizens to become active partners in shared decision-making and encouraging personalised care based on outcomes that matter to the person. We are keen to gather more feedback on this app. Please forward any feedback to ann.wales3@nhs.scot

 

 

Management of Bartholin’s cyst and abscess, Gynaecology (066)

Warning

Objectives

To provide guidance on the management of those presenting with and Bartholin’s cyst or abscess

Audience

All healthcare professionals involved in the care of women with a Bartholin’s cysts or abscess

Please report any inaccuracies or issues with this guideline using our online form

The Bartholin’s gland is a mucus secreting gland located bilaterally at the base of the labia minora, at the level of the hymen. When the duct becomes blocked, a cyst may form and the gland may be palpable. If the cyst becomes infected, an abscess may form which can cause severe pain. The life-time risk is approximately 3%. 

Patients will present with a painful unilateral swelling in the vagina. 

On examination, there will be a tender, erythematous swelling at 4 or 8 o’clock on the lateral vaginal wall. Tracking of the abscess along the vaginal wall may cause cellulitis. 

  • Inclusion cyst
  • Gartner duct cyst
  • Haematoma
  • Sebaceous cyst
  • Lipoma
  • Hidradenitis suppurativa
  • Endometriosis

A charcoal swab should be obtained from the cyst/abscess and sent for culture and sensitivity. It is estimated that >70% of cysts are culture sterile, and only 33% of abscess cultures are sterile.

Bartholin’s duct abscesses may be polymicrobial: E. coli (single most common pathogen), followed by infections including Staphylococcus aureus, Group B streptococci and Enterococci species. Neisseria gonorrohoea may be identified.

Additional appropriate swabs should be obtained for chlamydia and gonorrohoea if there is risk of a sexually transmitted infection. 

Biopsy

A biopsy may be indicated in women over 40 years old as there is an increased risk of adenocarcinoma of the Bartholin’s gland. 

This will depend on the severity and the duration of the patient’s symptoms in addition to patient preference.   

Recurrence rates are not consistently reported.  However, one RCT (WoMan trial) summarised that Marsupialisation and Word catheter recurrence at 12 months are similar (10-12%).   Where incision and drainage or needle aspiration is performed, recurrence is thought to be higher, and therefore should be avoided if possible.  The aim should being to create a new mucocutaneous junction between the wall of the cyst and the skin of the labia to allow continued drainage.

Conservative management, no signs of infection

Hot baths several times per day and simple analgesia.  In the absence of cellulitis, antibiotics are not indicated.

Conservative management, no surgical intervention with suggestion of mild infection with presence of cellulitis or offensive discharge.  A review of any previous swabs should be undertaken.

Where antibiotic treatment is required, suggested regimes are

Co-amoxiclav 625mg orally 8 hourly, total duration for 5 days

Or

Co-trimoxazole (Septrin) 960mg orally 12 hourly, total duration for 5 days (avoid 1st trimester pregnancy)

Surgical Management - Word Balloon Catheter

This treatment should be used first line in the surgical management of Bartholin’s cysts or abscesses. This is a very well tolerated procedure and has good operative success. 

The Word catheter kits contain the 3cm long catheter, a syringe for inflation and the scalpel. A local anaesthetic, such as 1% lidocaine, may be used to infiltrate the skin prior to the initial incision being made. Via a 5mm stab incision into the mucosal surface of the labia minora, just exterior to the hymen ring, within the introitus in the region of the normal duct opening. 

A charcoal swab should be obtained from the discharging fluid. 

The catheter is inserted and inflated with a maximum of 3ml of saline, as per the manufacturer’s guidelines. If the balloon is overfilled this may cause extra discomfort so the balloon should be deflated by extracting some saline. If the incision is made too large the catheter may fall out so an anchor suture may be required to hold it in place.

The patient can go home with the catheter in situ and usually this stays in for 4 weeks to encourage formation of an epithelialised fistula and prevent refilling of the abscess. A patient information leaflet should be given with a contact number for the gynaecology emergency service.

After 4 weeks, the catheter is deflated and removed. If the catheter falls out at home during this time it may be left out provided the patient’s symptoms are resolving. 

Where there are no signs of infection, antibiotic cover is not required.

Consideration should be made to cover with broad spectrum antibiotics if signs suggestive of an infection are present e.g. purulent offensive smelling discharge or signs of cellulitis.  A review of any previous swab results should be undertaken.

Where antibiotic treatment is required suggest

Co-amoxiclav 625mg orally 8 hourly, total duration for 5 days

or

Co-trimoxazole (Septrin) 960mg orally 12 hourly, total duration for 5 days (avoid 1st trimester pregnancy)

Surgical Management - Marsupialisation 

Where there is a recurrent abscess or if patient would prefer to avoid Word Catheter insertion, marsupialisation under a general anaesthetic should be performed. The purpose of this is to create a fistula and prevent further abscess formation. Packing is not routinely required. 

In theatre, a single dose of intravenous antibiotic cover should be given.

1.2g of co-amoxiclav, IV

or

900mg of clindamycin, IV

Consideration should be made to continue cover with broad spectrum antibiotics, particularly if signs suggestive of an infection are present e.g. purulent offensive smelling discharge or signs of cellulitis. 

Co-amoxiclav 625mg orally 8 hourly, total duration for 5 days

or

Co-trimoxazole (Septrin) 960mg orally 12 hourly, total duration for 5 days (avoid 1st trimester pregnancy)

This is not routinely required after marsupialisation of the cyst or abscess.

If patients have already been commenced on oral antibiotics, they may wish to complete the course. However, they do not routinely need to start treatment after the initial dose in theatre, if there are no signs suggestive of infection.

Simple vulval hygiene advice should include avoiding bubble baths, lotions or talcum powder. Sexual intercourse should be avoided until there is no pain or discharge. 

Editorial Information

Last reviewed: 14/06/2023

Next review date: 16/05/2026

Author(s): Joy SimpsonDr Joy Simpson, Consultant O&G PRM.

Version: 2

Approved By: Gynaecology Clinical Governance Group

Document Id: 066

Related resources
References

Balloon catheter insertion for Bartholin's cyst or abscess | Guidance and guidelines | NICE

Inserting an inflatable balloon to treat a bartholin’s cyst or abscess Interventional Procedure guidance 323. December 2009. National Institute for Health and Clinical Excellence (NICE)

Wechter Wu, Marzano and Haefner. Management of bartholin duct cyst and abscesses. A systematic review. Obstetrical and Gynaecolocal Survey; 64(6) 2009. 

BMJ Best Practice, Bartholin's cyst - Symptoms, diagnosis and treatment, August 2022.

Omole F et al. Bartholin Duct Cyst and Gland Abscess: Office ManagementAm Fam Physician. 2019;99(12):760-766

Kroese AJ et al. Word catheter and marsupialisation in women with a cyst or abscess of the Bartholin gland (WoMan-trial): a randomised clinical trial. BJOG. 2017 Jan;124(2):243-249.